Core Viewpoint - The recent leadership changes at China National Pharmaceutical Group Corporation (Sinopharm) indicate a potential shift in management strategy, as multiple key executives, including the chairman and general manager, have resigned due to retirement and work changes, with no new chairman announced yet [1][4][5]. Company Summary - Sinopharm announced the resignation of three key executives, including the chairman and general manager, due to retirement and work changes [1]. - Liu Yuetao, the current party secretary, will act as the general manager, and he, along with Zhou Bin, has been nominated as candidates for the eighth board of directors [1][5]. - The company has not yet disclosed a new chairman following the retirement of the previous chairman, Jiang Xiuchang, in November 2024 [4][5]. Industry Summary - Sinopharm operates primarily in pharmaceutical distribution, covering various business segments including drug distribution, retail, and logistics, with a strong presence in Beijing [6]. - The company is a leading player in the narcotic drug wholesale market, holding over 70% market share in the special narcotic drug distribution sector as of 2022 [9]. - The pharmaceutical distribution industry has faced challenges, with a significant slowdown in growth, as evidenced by a mere 0.6% year-on-year growth in 2024, marking the lowest growth rate in 15 years [11].

Group 1 - The board of directors of China National Pharmaceutical Group Corporation (referred to as "the company" or "China National Pharmaceutical") held its 25th meeting of the 8th board on June 2025, with all five directors present, including four independent directors [1][2] - The board unanimously approved the nomination of Liu Yuetao and Zhou Bin as candidates for the 8th board of directors, pending approval at the company's first extraordinary general meeting of shareholders in 2025 [1][2] - The board also approved the proposal for the party secretary Liu Yuetao to act as the general manager following the resignation of General Manager Tian Guotao due to work changes [2][3] Group 2 - The company will hold its first extraordinary general meeting of shareholders in 2025, with details disclosed on the Shanghai Stock Exchange website [2] - Liu Yuetao has held various positions within the company, including financial director and general manager, and has been the party secretary since June 2025 [2] - Both Liu Yuetao and Zhou Bin do not hold shares in the company and have no related party relationships with other directors, supervisors, senior management, or major shareholders [3][5]

Group 1 - The company will hold its first extraordinary general meeting of shareholders in 2025 on July 7 at 9:30 AM in Beijing [1][3] - The voting will be conducted through a combination of on-site and online voting systems provided by the Shanghai Stock Exchange [3][4] - The registration for attending the meeting will be open from June 30 to July 2, 2025, and shareholders must present identification and relevant documents [6][5] Group 2 - The meeting will review proposals that have already been approved by the company's board of directors [2][3] - Shareholders can vote through the Shanghai Stock Exchange's online voting system, with specific time slots for voting on the day of the meeting [1][4] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts for the same category of shares [5][4]

证券代码：600511 证券简称：国药股份 公告编号：临 2025-017 国药集团药业股份有限公司 特此公告。 | 姓名 | 离任职务 | 离任时 | 原定任期 | | 离任原因 | 是否继续 在上市公 司及其控 | 具体职务 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 间 | 到期日 | | | 股子公司 | （如适用） | 毕的公开 | | | | | | | | | | 承诺 | | | | | | | | 任职 | | | | 蒋昕 | 董事、战略委员 | 2025年6 | 2025 | 年 4 | 退休 | 否 | / | 否 | (一) 提前离任的基本情况 | | 会委员（召集 | 月 | 20 日 | 月 7 | 日 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 人）、提名委员 | | | | | | | | | | | | 会委员 | | | | | | | | | ...

证券代码：600511 证券简称：国药股份 公告编号：2025-019 股东大会召开日期：2025年7月7日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 国药集团药业股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 7 月 7 日 9 点 30 分 召开地点：北京市东城区永定门西滨河路 8 号院 7 楼中海地产广场西塔 8 层 会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 7 月 7 日 至2025 年 7 月 7 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东 ...

证券代码：600511 证券简称：国药股份 公告编号：临 2025-018 国药集团药业股份有限公司 第八届董事会第二十五次会议决议公告 该议案尚需提交公司 2025 年第一次临时股东大会审议。 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 一、 董事会会议召开情况 国药集团药业股份有限公司（以下简称"公司"或"国药股 份"）第八届董事会第二十五次会议通知及资料于 2025 年 6 月 16 日以书面、电子邮件等形式发出，会议于 2025 年 6 月 20 日 以现场结合通讯表决方式在北京召开。本次会议应到董事五名， 实到董事五名，其中四名独立董事参加了会议，全体董事共同推 举董事余兴喜先生主持本次会议，监事和部分高管列席会议，符 合《公司法》和《公司章程》的有关规定。 二、 董事会会议审议情况 本次会议审议并通过了如下决议： （一）以 5 票同意、0 票反对和 0 票弃权的结果审议通过《关 于提名董事候选人的议案》。 公司董事会提名刘月涛先生（简历见附件）、周滨先生（简 1 历见附件）为公司第八届董事会董事候选人，任期自 ...

Group 1 - The core index of the China Securities Index for Food and Major Consumer Goods Retail has shown a decline of 2.40% over the past month, 6.58% over the past three months, and 6.48% year-to-date [1] - The index is composed of listed companies in the food and drug retail sector, reflecting the overall performance of these companies, with a base date of December 31, 2004, set at 1000.0 points [1] - The top ten weighted companies in the index include Yonghui Supermarket (6.61%), Digital China (6.21%), Wancheng Group (4.68%), Shanghai Pharmaceuticals (4.41%), Yifeng Pharmacy (4.32%), Jiuzhoutong (3.86%), Kidswant (3.41%), Sinopharm (3.25%), Wangfujing (3.17%), and TianKang (3.09%) [1] Group 2 - The market segments represented in the index include 43.94% in pharmaceutical commerce, 21.32% in supermarkets and convenience stores, 20.29% in specialty retail, and 14.46% in department stores [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]

截至2025年6月13日收盘，国药股份（600511）报收于30.34元，较上周的30.51元下跌0.56%。本周，国 药股份6月10日盘中最高价报31.55元。6月13日盘中最低价报30.34元。国药股份当前最新总市值228.92 亿元，在医药商业板块市值排名4/31，在两市A股市值排名670/5150。 本周关注点 公司公告汇总：国药股份2024年年度权益分派实施，每股现金红利0.80元（含税） 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 A股每股现金红利0.80元（含税） 股权登记日：2025年6月17日 除权（息）日和现金红利发放日：2025年6月18日 差异化分红送转：否 分配方案：以方案实施前的公司总股本754502998股为基数，每股派发现金红利0.80元（含税）， 共计派发现金红利603602398.40元(含税） 分配实施办法：无限售条件流通股的红利委托中国结算上海分公司派发，控股股东国药控股股份 有限公司的现金红利由本公司直接发放 扣税说明： 对于个人股东及证券投资基金，持股期限超过1年的，股息红利所得暂免征 ...

证券代码：600511 证券简称：国药股份 公告编号：临 2025-016 国药集团药业股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/17 | － | 2025/6/18 | 2025/6/18 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 4 月 24 日的2024年年度股东大会审议通过。 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.80元（含税） 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本754,502,998股为基数，每股派发现金红利0.80 元（含税）， ...

Core Insights - The AMAC Wholesale Retail Trade Index (AMAC批零, H11045) increased by 1.3%, closing at 1617.5 points with a trading volume of 31.254 billion [1] - Over the past month, the index has risen by 2.93%, by 1.85% over the last three months, and by 0.73% year-to-date [1] Index Composition - The AMAC Wholesale Retail Trade Index is based on 43 industry classification indices, excluding manufacturing, and is compiled according to the classification guidelines from the China Securities Association [1] - The top ten weighted stocks in the index are: Huadong Medicine (5.33%), Yonghui Supermarket (3.05%), Digital China (2.87%), Shanghai Pharmaceuticals (2.83%), Wancheng Group (2.26%), Wuchan Zhongda (2.21%), Yifeng Pharmacy (2.19%), Jiuzhoutong (1.83%), Sinopharm (1.58%), and Kidswant (1.57%) [1] Market Distribution - The market distribution of the AMAC Wholesale Retail Trade Index shows that the Shenzhen Stock Exchange accounts for 53.12%, while the Shanghai Stock Exchange accounts for 46.88% [1] Industry Breakdown - In terms of industry composition, discretionary consumption accounts for 36.90%, healthcare for 31.52%, industrials for 22.28%, staples for 4.58%, energy for 2.78%, real estate for 1.27%, and financials for 0.67% [2]